HTLV 2022
  • Home
  • About
    • Committee
    • Conference Objectives
  • Program
    • 2022 Program
    • Keynote Speakers
    • Speaker Presentation Assistance
    • Abstract Submission
  • HTLV22 Call to Action
  • Registration
    • Scholarship Opportunities
  • Digital Toolkit
  • Why Sponsor
    • Sponsors
  • Contact Us
    • Privacy Policy
    • Terms and Conditions
  • Search
  • Menu Menu

    HTLV22


    PROGRAM &
    POSTER LISTING

    Join Our Mailing List

    KEY DEADLINES



    Abstract Submission: CLOSED


    Scholarship Application Deadline: CLOSED


    Standard Registration Deadline: CLOSED

    Sunday 8 MayMonday 9 MayTuesday 10 MayWednesday 11 MayOn-Demand Posters

    Day 1 of the conference will begin at the following times

    • Honolulu, HI, USA  – 19:00, Saturday, 7 May 2022
    • Phoenix, AZ, USA  – 22:00, Saturday, 7 May 2022
    • Baltimore, MD, USA  – 01:00, Sunday, 8 May 2022
    • Sao Paulo, Brazil  – 02:00, Sunday, 8 May 2022
    • London, UK  – 06:00, Sunday, 8 May 2022
    • Berlin, Germany  – 07:00, Sunday, 8 May 2022
    • Shanghai, China  – 13:00, Sunday, 8 May 2022
    • Tokyo, Japan  – 14:00, Sunday, 8 May 2022
    • Melbourne, Australia  – 15:00, Sunday, 8 May 2022
    • Auckland, New Zealand  – 17:00, Sunday, 8 May 2022

    To view the program in your local time, you can use the time zone converter tool here.

    Please note that the program times are not the same for each day of the conference. Please check the other days to confirm starting time. The below times are listed in Australian Eastern Standard Time (Melbourne).

    The program is in draft and is subject to change.

    15:00 – 16:30

    Opening Ceremony

    Chairs: Damian Purcell and Fabiola Martin

    Welcome to Country

    Committee Welcome and IRVA President Introduction – Professor Damian Purcell and Dr Fabiola Martin

    Australian Government Welcome – Hon Greg Hunt MP, Minister for Health and Aged Care

    Women and HTLV – Invited speaker: Sandra do Valle, Brazil

    20-year history of the Japanese HAM Patients Association – Invited speaker: Mr Shu Ishimoda, Smile Ribbon, Japan

    My Story: Lack of HTLV-1 STI screening and referral pathways in Australia –  Invited speaker: Ms Joanna Curteis, Patient Representative, Australia

    Keynote Address – HTLV Research Successes, set-backs and strategies – Professor Graham Taylor, Imperial College, London UK

    16:30 – 16:45

    Break

    16:45 – 17:47

    2. Viral-host Interactions for HTLV-1 Transmission

    Chairs: Helene Dutarte & Andrea Thoma-Kress

    Viral Transmission
    Invited speaker: Louis Mansky, Institute for Molecular Viroligy, USA

    #18 Role of tetraspanins in HTLV-1 biofilm formation
    Coline Arone, Université de Montpellier, France

    #33 The helicase-like transcription factor inhibits infectious replication of human T-cell leukemia virus type 1.
    Aurélie Beauvois, University of Liège, Belgium

    #91 Transient expression of HTLV-1 Tax induces epigenetic alterations and mimics early T-cell activation
    Daisuke Kurita, Kumamoto University, Japan

    #71 HTLV-1 Retrovirus is Not Detected by Dendritic Cells but Alters their Response to a Restimulation
    Auriane Carcone, Centre International de Recherche en Infectiologie, France

    Panel Discussion and Q&A (15mins)

    17:47 – 18:30

    Break

    18:30 – 19:32

    3. Unravelling the molecular events in pathogenesis of HTLV-1

    Chairs: Johan Van Weyenbergh & Anat Melamed

    #111 Selective clonal persistence of HTLV-1 in vivo: radial chromatin organization, integration site and host transcription
    Anat Melamed, Imperial College London, United Kingdom

    #80 HTLV-1 INFECTED CELLS MODULATE TARGET CELLS AND VIRAL SPREAD VIA EXTRACELLULAR VESICLES
    Fatah Kashanchi, George Mason University, USA

    #99 In vivo antagonistic role of the Human T-Cell Leukemia Virus Type 1 regulatory proteins Tax and HBZ
    Abdou Akkouche, American University Of Beirut, Lebanon

    #67 HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia / lymphoma
    Benjy Jek Yang Tan, Kumamoto University, Japan

    #50 Both HBZ Protein and mRNA upregulate TAp73 to promote the Warburg Effect in ATL cells
    Kosuke Toyoda, Kumamoto University School of Medicine, Japan

    Panel Discussion and Q&A (15mins)

    19:32 – 19:45

    Break

    19:45 – 20:55

    4. Who has HTLV-1 infection and where

    Chairs: John Kaldor and Belinda Greenwood Smith

    Global epidemiological aspects of HTLV-1 in the world with a focus on Africa, the largest HTLV-1 endemic area
    Invited Speaker: Antoine Gessain, Pasteur France, France

    #25 Prevalence and risk factors for human T-cell lymphotropic virus (HTLV) in blood donors in Brazil – a 10-year study (2007-2016).
    Carolina Miranda, Universidade Federal De Minas Gerais, Brazil

    #34 Prevalences Of HTLV, HIV And HBV In Patients Receiving Blood Transfusions In South Africa
    Reynier Willemse, Sanbs, South Africa

    #76 20 years of HTLV screening of blood donations in the UK
    Ruth Wilkie, NHSBT, United Kingdom

    #203 Retrospective study of Human T-cell Leukaemia Virus Type 1 & Adult T-cell Leukaemia/Lymphoma in Queensland, Australia.
    Robert Gibb, Pathology Queensland, Australia

    #61 Recent advances in HTLV-1 epidemiology.
    Edward Murphy, UCSF and Vitalant Research Institute, United States

    Panel Discussion and Q&A (15mins)

    To view the program in your local time, you can use the time zone converter tool here.

    Day 2 of the conference will begin at the following times

    • Honolulu, HI, USA  – 11:00, Sunday, 8 May 2022
    • Phoenix, AZ, USA  – 14:00, Sunday, 8 May 2022
    • Baltimore, MD, USA  – 17:00, Sunday, 8 May 2022
    • Sao Paulo, Brazil  – 18:00, Sunday, 8 May 2022
    • London, UK  – 22:00, Sunday, 8 May 2022
    • Berlin, Germany  – 23:00, Sunday, 8 May 2022
    • Shanghai, China  – 05:00, Monday, 9 May 2022
    • Tokyo, Japan  – 06:00, Monday, 9 May 2022
    • Melbourne, Australia  – 07:00, Monday, 9 May 2022
    • Auckland, New Zealand  – 09:00, Monday, 9 May 2022

    Please note that the program times are not the same for each day of the conference. Please check the other days to confirm starting time.

    The below times are listed in Australian Eastern Standard Time (Melbourne)

    07:00 – 08:02

    5. Animal models for HTLV

    Chairs: Luc Willems and Patrick Green

    #145 Bovine leukemia virus antisense transcription regulates viral replication, affects gene expression and directs host cell fate
    Thomas Joris, Université de Liège, Belgium

    #74 Single-cell NGS methods to track tumor precursor cells in HTLV-1 and BLV leukemia models
    Jerome Wayet, Uliege, Belgium

    #125 CD8+ cell depletion results in an increase in proviral loads in HTLV-1-infected cynomolgus macaques
    Midori Nakamura-Hoshi, National Institute of Infectious Diseases, Japan

    #72 Transient viral activation in HTLV-1-infected macaques treated with pomalidomide
    Anna Gutowska, National Institutes Of Health, Vaccine Branch, United States

    #24 The actin-bundling protein Fascin contributes to HTLV-1-induced lymphomagenesis in an ATLL xenograft mouse model
    Andrea K. Thoma-Kress, Universitätsklinikum Erlangen, Virologisches Institut, Germany

    #129 Combination antiretroviral therapy and MCL1 inhibition mitigate HTLV-1 infection in vivo
    James Cooney, The Walter and Eliza Hall Institute, Australia

    #75 Intragenic viral enhancer of HTLV-1 is dispensable for in vitro immortalization and in vivo persistence
    Victoria Maksimova, The Ohio State University, United States

    Panel Discussion and Q&A (25mins)

    08:02 – 08:15

    Break

    08:15 – 09:17

    6. How can testing improve clinical management?

    Chairs: Philippa Hetzel and Junji Yamauchi

    History of the HAM/TSP biomarker research
    Invited Speaker: Yoshihisa Yamano, St. Marianna University School of Medicine, Japan

    #126 Seroprevalence of neutralising antibodies in an HTLV-1c+ First Nations cohort from central Australia.
    Samantha Gimley, The Peter Doherty Institute For Infection And Immunity, Australia

    #153 Development of a pan-HTLV-1 Proviral Load Assay in Australia
    Nick Vandegraaff, NRL/SVI, Australia

    #83 Systemic cytokines and GlycA discriminate disease status and predict corticosteroid response in HTLV-1-associated neuroinflammation
    Tatiane Assone, Fmusp, Brazil

    #123 Flow cytometric assessment of T cell clonality for early detection of ATL: experience in the clinic
    Aileen Rowan, Imperial College London, UK

    Panel Discussion and Q&A (15mins)

    09:17 – 09:45

    Break

    09:45 – 10:47

    7. Clinical manifestations and biomarkers of disease during HTLV infection

    Chairs: Yoshi Yamano and Mari Kannagi

    Overall picture of genetic, epigenetic, and transcriptomic characteristics in ATL and HAM/TSP.
    Invited Speaker: Makoto Yamagishi, The University of Tokyo, Tokyo, Japan

    #136 Genome-wide association study of HAM/TSP susceptibility in Brazil reveals both immune and neural genetic links
    Johan Van Weyenbergh, Ku Leuven, Belgium

    #69 NGS quantification of viral clonal architecture identifies HTLV-1 asymptomatic carriers at high risk of progression to aggressive leukemia
    Snehal Dilip Karpe, Laboratory of Viral Oncogenesis, Institut Jules Bordet, ULB & Unit of Animal Genomics, Belgium

    #26 Role Of CTCF In Htlv-1 DNA Methylation, Gene Expression And Pathogenesis
    Ancy Joseph, Washington University in Saint Louis, United States

    #142 Analysis of neuroinflammatory biomarkers in HTLV-1-associated neurological disorders
    Marzia Puccioni, Universidade Federal do Estado do Rio de Janeiro – UNIRIO, Brazil

    Panel Discussion and Q&A (15mins)

    10:47 – 11:00

    Break

    11:00 – 12:02

    8. Key populations – Understanding and responding to HTLV in Vulnerable and First Nations Peoples

    Chairs: Eduardo Gotuzzo and Ricardo Ishak

    HTLV among vulnerable and indigenous communities in Brazil
    Invited Speaker: Antonio Vallinoto, Universidade Federal do Pará, Brazil

    HTLV-1 in Mahad/Iran: A Patient Perspective

    #63 A qualitative study exploring perceptions to the human T cell leukaemia virus type 1 in Central Australia: Barriers to preventing transmission in a remote Aboriginal population
    Fiona Fowler, Alice Salomon University of Applied Science, Australia

    #133 Immune activation and dysfunction are defining characteristics of every HTLV-1c infection
    Ashley Hirons, University Of Melbourne, Australia

    #116 Determinants for the HTLV-1 maternal-to-child Transmission.
    Gabriela Prates, Institute of Tropical Medicine, Brazil

    Panel Discussion and Q&A (15mins)

    12:02 – 12:15

    Break

    12:15 – 13:15

    Sponsored Satellite Session – Cybernics Medical Innovation with Wearable Cyborg HAL

    Chairs: Yoshi Yamano and Charles Bangham

    Speaker: Yoshiyuki Sankai, President and CEO of CYBERDYNE Inc. Professor, Executive Research Director of Center for Cybernics Research, Director of F-MIRAI (R&D Center for Frontiers of MIRAI in Policy and Technology), University of Tsukuba, Japan

    To view the program in your local time, you can use the time zone converter tool here.

    Day 3 of the conference will begin at the following times

    • Honolulu, HI, USA  – 19:00, Monday, 9 May 2022
    • Phoenix, AZ, USA  – 22:00, Monday, 9 May 2022
    • Baltimore, MD, USA  – 01:00, Tuesday, 10 May 2022
    • Sao Paulo, Brazil  – 02:00, Tuesday, 10 May 2022
    • London, UK  – 06:00, Tuesday, 10 May 2022
    • Berlin, Germany  – 07:00, Tuesday, 10 May 2022
    • Shanghai, China  – 13:00, Tuesday, 10 May 2022
    • Tokyo, Japan  – 14:00, Tuesday, 10 May 2022
    • Melbourne, Australia  – 15:00, Tuesday, 10 May 2022
    • Auckland, New Zealand  – 17:00, Tuesday, 10 May 2022

    Please note that the program times are not the same for each day of the conference. Please check the other days to confirm starting time.

    The below times are listed in Australian Eastern Standard Time (Melbourne)

    7:00 – 8:45

    IRVA AGM

    Welcome all existing and new IRVA members: Membership Secretary (FG) & President (FM)

    Introductions to Board of Directors and Executive Committee members: Secretary (PJ)

    President’s Report: President

    Treasurer’s Report: Treasurer (AP)

    Award Ceremony: Award Secretary (OH) & President

    Closure: Secretary

    15:00 – 16:02

    9. HTLV-1 Community Perspective

    Chairs: Fabiola Martin and Lloyd Einsendel

    Invited Speaker Presentation
    Achilea Bittencourt, Brazil

    #113 HTLV Channel: Increasing awareness about HTLV
    Carolina Rosadas, Imperial College London, United Kingdom

    #156 The Epidemiology and clinical manifestations of the human T cell leukaemia virus Type 1C in remote Australian Aboriginal communities
    Lloyd Einsiedel, Peter Doherty Institute, Australia

    #49 Evidence of zoonotic and nosocomial transmission of htlv-1 in large survey in rural population of central Africa
    Jil-Lea Ramassamy, Institute Pasteur, France

    #97 The UK’s HTLV National Register: a unique cohort to inform disease progression
    Katy Davison, Public Health England, United Kingdom

    Panel Discussion and Q&A (15mins)

    16:02 – 16:15

    Break

    16:15 – 17:17

    10. Cutting-edge genomics approaches to improve our understanding of HTLV-1 associated disease

    Chairs: Anne Van den Broeke and Franck Mortreux

    Advanced sequencing technologies reveal new insights into oncogenic mechanism induced by HTLV-1
    Invited Speaker: Dr Yorifumi Satou

    #52 Chronological genome and single-cell epigenome/transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma
    Makoto Yamagashi, The University of Tokyo, Japan

    #105 Dominant clones in high-risk HTLV-1 carriers have a genetic and transcriptomic profile closely resembling ATL clones
    Sonia Wolf, Imperial College, United Kingdom

    #102 Changes in 3D chromatin architecture upon NF-κB activation by TAX involve transcriptional and alternative splicing regulations
    Paul Marie, Laboratory of Biology and Modelling of the Cell, France

    #43 The dynamics and consequences of HTLV-1 Tax expression in naturally infected T-cell clones
    Saumya Ramanayake, Imperial College London, United Kingdom

    Panel Discussion and Q&A (15mins)

    17:17 – 17:45

    Break

    17:45 – 19:02

    11. Prevention Strategies

    Chairs: Graham Taylor and Beatrice Macchi

    Public health response to HTLV
    Invited Speaker: Peter Figueroa, Jamaica

    #54 Cellular proteins of the vesicular trafficking pathway regulate HTLV-1 retention in viral biofilm and infectivity of chronically infected cells
    Helene Dutartre, Inserm. Ciri – Lyon, France

    #37 Cryo-EM structures of the deltaretroviral intasome in complex with the host factor Protein Phosphatase 2A subunit B56γ and HIV integrase inhibitors.
    Goedele N. Maertens, Imperial College London, United Kingdom

    #109 HTLV seroprevalence among HIV PrEP users in England
    Daniel Bradshaw, Uk Health Security Agency, United Kingdom

    #85 Strengths, weaknesses, opportunities & threats for the implementation of public health policies on htlv-1 in Brazil: a swot analysis
    Ricardo Ishak, Universidade Federal Do Para, Brazil

    HTLV-1: Applying a global public health approach – Challenges and opportunities
    Invited Speaker: Meg Doherty, World Health Organisation, Switzerland

    Panel Discussion and Q&A (15mins)

    19:02 – 19:15

    Break

    19:15 – 20:25

    12. Clinical Trials (phase 1-IV)

    Chairs: Lucy Cook and Masao Matsuoka

    Novel approaches to future management of ATLL
    Invited Speaker: Makoto Yoshimitsu, Kagoshima University Hospital, Japan

    #39 First-in-human experience with hypomethylating agents and Venetoclax in Relapsed/Refractory North American Adult T-Cell Leukemia and Lymphoma patients (NA ATLL)
    R. Alejandro Sica, Montefiore Einstein Center For Cancer Care, United States

    #148 A Phase II Trial of Belinostat as Consolidation Therapy with Zidovudine for Adult T-Cell Leukemia-Lymphoma (ATLL): Interim Results
    Juan Carlos Ramos, University of Miami- Sylvester Comprehensive Cancer Center, United States

    #121 Efficacy and safety of brentuximab vedotin in adult T-cell leukemia/lymphoma
    Nobuaki Nakano, Imamura General Hospital, Japan

    #168 Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukemia-lymphoma (ATL)
    Hiro Tatetsu, Kumamoto University Hospital, Japan

    #64 A randomized controlled trial on corticosteroid therapy for HTLV-1-associated myelopathy/tropical spastic paraparesis in Japan (HAMLET-P trial)
    Junji Yamauchi, St. Marianna University, Japan

    Panel Discussion and Q&A (15mins)

    To view the program in your local time, you can use the time zone converter tool here.

    Day 4 of the conference will begin at the following times

    • Honolulu, HI, USA  – 11:00, Tuesday, 10 May 2022
    • Phoenix, AZ, USA  – 14:00, Tuesday, 10 May 2022
    • Baltimore, MD, USA  – 17:00, Tuesday, 10 May 2022
    • Sao Paulo, Brazil  – 18:00, Tuesday, 10 May 2022
    • London, UK  – 22:00, Tuesday, 10 May 2022
    • Berlin, Germany  – 23:00, Tuesday, 10 May 2022
    • Shanghai, China  – 05:00, Wednesday, 11 May 2022
    • Tokyo, Japan  – 06:00, Wednesday, 11 May 2022
    • Melbourne, Australia  – 07:00, Wednesday, 11 May 2022
    • Auckland, New Zealand  – 09:00, Wednesday, 11 May 2022

    The below times are listed in Australian Eastern Standard Time (Melbourne)

    07:00 – 08:02

    13. Non-Pharmacological/Behavioural Science

    Chairs: Mrs Adine Adonis and Dr Mirna Biglione

    Physiotherapy for Individuals with HAM/TSP
    Invited Speaker: Katia Sá, Escola Bahiana de Medicina e Saúde Pública, Brazil

    #38 Neurofunctional physical therapy protocol in patients with associated myelopathy to HTLV-1 (HAM).
    Denise Goncalves, Ufmg, Brazil

    #2 Prevalence and factors associated with depression and anxiety in people living with HTLV-1: A systematic review with meta-analysis and meta-regression
    Lucca Souza, Federal University of Bahia, Brazil

    #90 Multinational cross-sectional study on provision of HTLV care for blood donors with HTLV reactive serology
    Fabiola Martin, University Of Queensland, Australia

    #128 Defining research priorities for people living with HTLV-1 through patient/public involvement and engagement (PPIE) workshops
    Adine Adonis, Imperial College Healthcare NHS Trust, United Kingdom

    Panel Discussion and Q&A (15mins)

    08:02 – 08:15

    Break

    08:15 – 09:17

    14. Responding to co-infections

    Chairs: Marzia Puccioni & Carolina Rosadas

    Overview of HTLV-1 co-infections
    Invited Speaker: Fernanda Grassi, Fiocruz, Brazil

    #35 Human T-Lymphotropic virus type 1 and Human Immunodeficiency Virus co-infection in rural Gabon, Central Africa
    Augustin Ghislain MOUINGA ONDEME, International Centre for Medical Research, Gabon

    #202 COVID infection in patients with Human T-cell Leukemia Virus Type 1 (HTLV-1) infection, in Peru. Cases report
    Eduardo Gotuzzo, Universidad Peruana Cayetano Heredia

    #8 COVID-19 in individuals with HTLV-1 infection in Rio de Janeiro
    Stephanie Monnerat, Universidade Federal Do Estado Do Rio De Janeiro, Brazil

    #107 SARS-COV-2 Vaccination in people living with HTLV: vaccine hesitancy and antibody response
    Divya Dhasmana, National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, London, United Kingdom

    Panel Discussion and Q&A (15mins)

    09:17 – 09:45

    Break

    09:45 – 10:47

    15. Prospects for HTLV-1 preventive and therapeutic vaccines

    Chairs: Genoveffa Franchini and Damian Purcell

    A safe attenuated vaccine that protects from bovine leukemia virus infection in herds
    Luc Willems, FNRS-ULiege, Belgium

    #155 Preclinical evaluation of a subunit vaccine platform for HTLV-1
    Keith Chappell, The University Of Queensland, Australia

    #58 Potential anti-ATL therapeutic vaccine using short-term cultured autologous peripheral blood mononuclear cells: preclinical evidence in vitro and in vivo
    Mari Kannagi, Department of Microbiology, Kansai Medical University, Japan

    #46 In vivo and in vitro immunogenicity of novel MHC class I presented epitopes for a therapeutic peptide-based vaccine against HTLV-1.
    Rashida Ginwala, Department of Medicine, Imperial College, United Kingdom

    Panel Discussion
    Luc Willems, Tetsuro Matano, Charles Bangham, Pooja Jain, Keith Chappell, Mari Kannagi, Rashida Ginwala, and Joanna Curteis

    10:47 – 11:00

    Break

    11:00 – 12:30

    16. Closing Plenary

    Chairs: Fabiola Martin and Damian Purcell

    Keynote Address – HIV vaccine efforts relevant the development of preventive HTLV-1 vaccines 
    Dr Genoveffa Franchini, National Institutes of Health, Vaccine Branch, USA

    Patient Presentation – Invited Speaker: Joanna Curteis

    Poster Awards

    Closing Remarks and future announcements

    Posters are listed by theme and alphabetical order of author.

    Poster listing is subject to change.

    Please click on the poster name to view the abstract.

    Basic Science

    PO001 – High-resolution structural analysis of capsid-capsid interactions reveals novel insights into HTLV-1 particle morphology

    William Arndt, University Of Minnesota – Twin Citites, United States


    PO003 – Enriched cell pathways associated with dysregulated miRNAs expression by HTLV-2 infection

    Andrea Corsi, University Of Verona, Italy


    PO005 – HTLV-1 Subtype C chronically infected cell line clones for the in-vitro study of viral transmission and pathogenesis.

    Peter Ellenberg, University of Melbourne, Australia


    PO006 – Immunophenotypic characterization in CSF of patients with virus-associated neuroinflammatory diseases

    Yoshimi Enose-Akahata, Viral Immunology Section, NINDS, NIH, United States


    PO007 – CSF antibody profiling of patients with HTLV-1 associated myelopathy/ tropical spastic paraparesis using VirScan

    Yoshimi Enose-Akahata, Viral Immunology Section, NINDS, NIH, United States


    PO008 – EPZ015666, a PRMT5 inhibitor, selectively targets HTLV-1-infected T-cell lines in vitro and in vivo

    Kyle Ernzen, The Ohio State University, United States


    PO009 – HTLV-1 proviral load in vaginal fluid correlates directly with proviral load in peripheral blood mononuclear cells of infected women

    Alisson Firmino, Bahiana School Of Medicine And Public Health, Brazil


    PO010 – Immunogenic synthetic peptides: candidates for HTLV test of point of care development

    Victor Folgosi, Laboratório De Dermatologia e Imunodeficiências, Instituto De Medicina Tropical De São Paulo / USP, Brazil


    PO011 – Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of Adult T cell Leukemia

    Greta Forlani, University Of Insubria, Italy


    PO012 – Bio-id proximity mapping identifies cep63 as a centrosomal target of htlv-1 tax oncoprotein

    Janelle Gauthier, CIRI, Centre International de Recherche en Infectiologie, France


    PO013 – Cerebrospinal fluid chitotriosidase-1 as a candidate biomarker for the progression of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)

    Yago Gomes, Ioc/fiocruz, Brazil


    PO014 – Transcriptomic analysis of HTLV-1 infection in T-cells reveals novel insights into virus-host cell interactions important for virus assembly and infectious spread

    Heather Hanson, University Of Minnesota, United States


    PO015 – Induction of the tumor marker Fascin by HTLV Tax-1 and Tax-2 is linked to alternative NF-κB signaling

    Stefanie Heym, Institute Of Clinical And Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany


    PO004 – Arsenic/Interferon α-induced selective eradication of leukemia-initiating activity in adult T cell leukemia: Loss of interleukin-10 and activation of innate immune microenvironment response

    Rita Hleihel, American University Of Beirut, Lebanon


    PO017 – Simplified detection method for the clonality of Bovine leukemia virus-infected cells and early diagnosis of Enzootic Bovine Leukosis

    Md Belal Hossain, Kumamoto University, Japan


    PO018 – Improved cytotoxicity of antiretroviral drug Lopinavir in combination with flavonoid Apigenin in a manner similar to the antagonist of Aryl-hydrocarbon receptor

    Dominic Sales, Drexel University, United States


    PO019 – Role of cell surface and soluble/extra vesicular immune checkpoint molecules in determining the quality of anti-HTLV-1 CD8 T-cell response.

    Julie Joseph, Drexel University, United States


    PO020 – 3’LTR occupancy by MEF-2C/Menin drives Adult T-cell Leukemia via HBZ

    Pooja Jain, Drexel University, United States


    PO022 – Extracellular vesicles (EVs) from HTLV-1 infected cells possess subpopulation-specific malignant transformation effects upon uninfected cells.

    Zach Cuba, George Mason University, United States


    PO024 – Effect of Extracellular Vesicles (EVs) from HTLV-1 on Cell Proliferation via “Autocrine” Feedback Loop

    Sarah Al Sharif, George Mason University, United States


    PO025 – Wiskott-Aldrich syndrome protein (WASP) is a novel interaction partner of HTLV-1 p8 and may contribute to p8 transfer between cells

    Laura M. Kemeter, Institute Of Clinical And Molecular Virology, Friedrich-alexander Universität Erlangen-nürnberg, Germany


    PO026 – Temporal host transcription during spontaneous HTLV-1 proviral reactivation

    Helen Kiik, Imperial College London, United Kingdom


    PO027 – Elucidating the formation of a multimeric protein complex with HTLV-1 Tax and its impact on viral replication

    Stephan Kohrt, Institute Of Clinical And Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany


    PO028 – HBZ-related dysregulation of circular RNAs (circRNA) expression in ATLL

    Julien Ladet, Laboratory of Biology and Modelling of the Cell, France


    PO029 – ERK-signaling regulates Human T Cell Leukemia Virus Type 1 RNA stability and gene expression in latently-infected CD4 T cells

    hsin-ching lin, Rutgers University, United States


    PO030 – Investigating the Role of Base-Triples in the HTLV-1 pro-pol Frameshift Site Pseudoknot

    Madison Maille, Loyola Marymount University, United States


    PO032 – Neurofilament Light in HTLV-1 Associated Myelopathy: Evaluation of Clinical, Radiological and Immuno-virological correlations

    Yair Mina, NINDS, NIH, United States


    PO033 – Interactome and epigenetic functions of HTLV-1 Tax

    Jun Mizuike, The University of Tokyo, Japan


    PO034 – The retroviral transporter Rex hijacks the RNA helicase UPF1 in a CRM1 dependent manner.

    Vincent Mocquet, ENS De Lyon, France


    PO035 – KDR/VEGFR2 interacts with HTLV-1 Tax and prevents its autophagic degradation

    Suchitra Mohanty, Penn State University College Of Medicine, United States


    PO037 – Role of Monocytes, CTL and NK cells in primary HTLV-1 infection

    Ramona Moles, National Institutes Of Health, Vaccine Branch, United States


    PO038 – Identification of chloroquine/hydroxychloroquine as candidate therapeutic agents for adult T-cell leukemia/lymphoma

    Shingo Nakahata, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Japan


    PO039 – Whole genome sequence analysis of human T-cell leukemia virus type 1 in Peru

    Shingo Nakahata, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Japan


    PO040 – Analysis in the mechanism of co-operative and mutual regulation among viral proteins in HTLV-1 infection

    Nakano Nakano, Grad. Sch. Frontier Sci., The University of Tokyo, Japan


    PO041 – Valemetostat, an EZH1/2 inhibitor, suppresses HTLV-1 infection in a humanized mouse model

    Tokifumi Odaka, Kansai Medical University, Japan


    PO043 – Analysis of EV Signatures from HAM/TSP Patient CSF

    Michelle Pleet, NIH/NINDS, United States


    PO044 – Modeling tumor-bone interactions in ATL with HTLV-1-infected peripheral blood cell lines

    Nitin Pokhrel, Washington University in St Louis, United States


    PO045 – Role of protein kinase cβ in adult t-cell leukemia lymphoma

    Lee Ratner, Washington University, United States


    PO046 – Viral clonal landscape and tumor progression: lessons from tumor-resistant sheep in the BLV leukemia model

    Anne-sophie Reuter, Uliege, Belgium


    PO047 – Construction and Characterization of two Chimeric HTLV-1AC infectious Molecular Clones

    Sarkis Sarkis, National Institutes Of Health, Vaccine Branch, United States


    PO048 – Evaluation of quantification method of HTLV-1 proviral load in white blood cells using whole blood

    Tomoo Sato, St. Marianna University School of Medicine, Japan


    PO049 – Panobinostat and Romidepsin enhance Tax transcription but only moderately Tax protein in Tax-expressing, HTLV-1-infected cultured, and patients’ T-cells

    Annika Schnell, Institute Of Clinical And Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany


    PO050 – The endogenous HBZ interactome in ATL leukemic cells reveals an unprecedented complexity of host interacting partners involved in RNA splicing

    Mariam Shallak, University Of Insubria, Italy


    PO051 – Characterizing the transfer of the mobile HTLV-1 accessory protein p8

    Florian Simon, Universitätsklinikum Erlangen, Germany


    PO052 – Gene targeted editing to disable the oncogenic retrovirus HTLV-1

    Susan Smith, The Ohio State University, United States


    PO053 – Determining How Stem-loop Structure Thermodynamic Stability Influences Frameshift Efficiency at the HTLV-1 gag-pro Frameshift Site

    Mary Soliman, Loyola Marymount University, United States


    PO054 – In vivo loss of PD-1 accelerates neoplastic and inflammatory diseases induced by HTLV-1 bZIP factor

    Miyu Sonoda, Departments Of Hematology, Rheumatology, And Infectious Diseases, Kumamoto University Hospital, Japan


    PO056 – Precise excision of htlv-1 provirus with designer-recombinases

    Andrea K. Thoma-Kress, Universitätsklinikum Erlangen, Virologisches Institut, Germany


    PO057 – Immunomodulatory drugs (IMiDs) and CelMod-mediated growth suppression of Adult T-Cell Lymphoma/Leukemia (ATL) cells: Functional linkage between Cereblon targets and their down-stream effectors.

    Yu Wang, Department of Microbiology, Oita University Faculty of Medicine, Japan


    PO058 – In-depth proteomic analysis of human T-cell leukemia virus type 1 particles reveals novel insights into virus-host cell interactions

    Nora Willkomm, University Of Minnesota, United States


    PO059 – HTLV-1 expression reduces local chromatin looping

    Hiroko Yaguchi, Imperial College London, United Kingdom


    PO060 – Evaluation of the risk of HTLV-1-associated diseases by analyzing the host immune responses and proviral load

    Asami Yamada, Kumamoto University, Japan

    Clinical Research - ATL

    PO061 – Adult T-cell leukemia/lymphoma in French Guiana: Real-life data from 2009 to 2019

    Karim Abdelmoumen, Université De La Réunion, France


    PO092 – Flow cytometric assessment of T cell clonality for early detection of ATL: comparison with RNA-Seq

    Patricia Watber, Imperial College, United Kingdom


    PO062 – Flavopiridol inhibits adult T-cell leukemia/lymphoma cell growth by IRF4 downregulation via super-enhancer suppression

    Hikaru SAKAMOTO, Department of Hematology, Nagasaki University Hospital, Japan


    PO063 – Allogeneic Hematopoietic Stem Cell Transplant (HCT) Outcomes in the Afro-Caribbean Population: A Single Center Study.

    Ankit Shah, University Of Miami Miller School Of Medicine, United States


    PO064 – Fluctuation of HTLV-1 provirus loads in long survival patients with ATL underwent allogeneic hematopoietic cell transplantation

    Atae Utsunomiya, Imamura General Hospital, Japan

    Clinical Research - HAID (HTLV-1 associated inflammatory disease)

    PO065 – Neuropathic Pain Profiling in Retroviral Infection (NIPPR):Preliminary results of an observational study of people with HTLV-1 infection

    Adine Adonis, Imperial College Healthcare NHS Trust, United Kingdom


    PO066 – Daily low-dose prednisone in patients with HTLV-1-associated myelopathy: prospective cohort study in a referral center in Brazil

    Tatiane Assone, Fmusp, Brazil


    PO067 – By ignoring HTLV-1, is our understanding of the global burden of scabies only skin deep?

    Beatrice Cockbain, Imperial College, United Kingdom


    PO069 – Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis: A Phase I/II Clinical Trial

    Anita Fletcher, National Institute Of Neurological Disease And Stroke/national Institues Of Health, United States


    PO070 – Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy: A nationwide registry study in Japan

    Naoki Iijima, Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan


    PO071 – il-10 and ifn-γ genes polymorphism in htlv-1 infected individuals and their possible relationship with ham/tsp development

    Ana Carolina Marinho Monteiro Lima, Universidade Católica Do Salvador, Brazil


    PO072 – Drugs efficacy on htlv-1-associated myelopathy/tropical spastic paraparesis treatment: a systematic review

    Ana Carolina Marinho Monteiro Lima, Universidade Católica Do Salvador, Brazil


    PO073 – The imaging spectrum of HTLV-1 related neurological disease”

    Cillian McNamara, Imperial College NHS Healthcare Trust, United Kingdom


    PO074 – Immunopathogenic CSF TCR repertoire signatures in HAM/TSP

    Satoshi Nozuma, Kagoshima University, Japan


    PO075 – Case series: Pediatric T-cell Human Lymphotropic Virus type 1 and its clinical expression

    Juan Rojas, Valle University, Colombia


    PO076 – HTLV Elite Controllers: A diagnostic challenge and a learning opportunity

    Carolina Rosadas, Imperial College London, United Kingdom


    PO077 – Expanded Spectrum of Clinical Manifestations associated to HTLV-1 infection

    Vicente Soriano, Universidad Internacional de La Rioja, Spain

    Prevention, Epidemiology and Public Health

    PO078 – the homeless population as the center of htlv control policies

    Sarah Cassino, Unirio, Brazil


    PO081 – prevalence of htlv-associated uveitis in patients of salvador. brazil

    Daniele Ozores, Escola Bahiana De Medicina E Saúde Pública, Brazil


    PO082 – HTLV-Covid-19 online survey: A novel experience through the pandemic for those living with HTLV

    Pullukkutti Arachchige Dona Manori Piyumi Perera, National Std/aids Control Programme, Sri Lanka


    PO084 – From presential to virtual: an multidisciplinary experience of htlv center iin salvador, brazil during the sars-cov-2 pandemic

    José Guilherme Reis-Oliveira, Escola Bahiana De Medicina E Saúde Pública (EBMSP), Brazil


    PO085 – Profile of covid-19 vaccinated members of an association of people living with htlv (htlvida) in bahia, brazil

    José Guilherme Reis-Oliveira, Escola Bahiana De Medicina E Saúde Pública (EBMSP), Brazil


    PO086 – HTLV screening In Spain should be universal in pregnant women and persons tested for sexually transmitted infections

    Vicente Soriano, Universidad Internacional de La Rioja, Spain


    PO087 – Late presentation of HTLV-1 infection is more frequent in native Spaniards than in migrants from endemic regions

    Vicente Soriano, Universidad Internacional de La Rioja, Spain


    PO088 – Self-perceived quality of life of asymptomatic htlv infected individuals

    Ruth Wilkie, NHSBT, United Kingdom

    Social Science & Community Forum

    PO091- fake news in covid era and its impact beyond sars-cov-2: htlv-1 case

    Carolina Rosadas, Imperial College London, United Kingdom

    Copyright 2021 by ASHM Conference & Events Division | info@htlvconference2022.com | +61 2 8204 0770
    Scroll to top